Medtronic Engager™ bioprosthesis for transapical transcatheter aortic valve implantation

EuroIntervention

Volumn 9, Issue , 2013, Pages S97-S100

  Sündermann, Simon H ^a   Holzhey, David ^b   Bleiziffer, Sabine ^c   Treede, Hendrik ^d   Falk, Volkmar ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF LEIPZIG HEART CENTER   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY HEART CENTER HAMBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALL CAUSE MORTALITY; AORTIC REGURGITATION; APPLICATION SITE REACTION; ARTICLE; BLEEDING; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; DEVICE SAFETY; EQUIPMENT DESIGN; FEASIBILITY STUDY; FOLLOW UP; HEART INFARCTION; HUMAN; MULTIPLE ORGAN FAILURE; PACEMAKER IMPLANTATION; POSTOPERATIVE PERIOD; PRESSURE GRADIENT; TRANSCATHETER AORTIC VALVE IMPLANTATION; TRANSLUMINAL VALVULOPLASTY; AORTA VALVE; AORTA VALVE REGURGITATION; AORTA VALVE STENOSIS; BIOPROSTHESIS; CLASSIFICATION; EQUIPMENT; HEART VALVE PROSTHESIS; HEART VALVE REPLACEMENT; INCIDENCE; METHODOLOGY; PROSTHESIS; STENT; TREATMENT OUTCOME; VERY ELDERLY;

ALLOY; NITINOL;

AGED, 80 AND OVER; ALLOYS; AORTIC VALVE; AORTIC VALVE INSUFFICIENCY; AORTIC VALVE STENOSIS; BALLOON VALVULOPLASTY; BIOPROSTHESIS; FEASIBILITY STUDIES; HEART VALVE PROSTHESIS; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; INCIDENCE; PROSTHESIS DESIGN; STENTS; TREATMENT OUTCOME;

EID: 84903504966     PISSN: 1774024X     EISSN: 19696213     Source Type: Journal    
DOI: 10.4244/EIJV9SSA19     Document Type: Article

References (9)

1. Sündermann SH, Grünenfelder J, Corti R, Rastan AJ, Linke A, Lange R, Falk V, Bleiziffer S. Feasibility of the EngagerTM aortic transcatheter valve system using a flexible over-the-wire design. Eur J Cardiothorac Surg. 2012;42:e48-52.
2. Holzhey, DM, Linke A, Treede H, Baldus S, Bleiziffer S, Opitz A, Boergermann J, Scholtz W, Vanoverschelde J, Falk V. Intermediate follow-up results from the EngagerTM Multi-center European Pivotal Trial. Presented at the Annual Meeting of the Society of Thoracic Surgeons, Los Angeles, CA, January 28, 2013.
3. Binder RK, Webb JG, Toggweiler S, Freeman M, Barbanti M, Willson AB, Alhassan D, Hague CJ, Wood DA, Leipsic J. Impact of post-implant SAPIEN XT geometry and position on conduction disturbances, hemodynamic performance, and paravalvular regurgitation. JACC Cardiovasc Interv. 2013;6:462-8.
4. Steinberg BA, Harrison JK, Frazier-Mills C, Hughes GC, Piccini JP. Cardiac conduction system disease after transcatheter aortic valve replacement. Am Heart J. 2012;164:664-71.
5. Hoffmann R, Herpertz R, Lotfipour S, Aktug Ö, Brehmer K, Lehmacher W, Autschbach R, Marx N, Lotfi S. l. Impact of a new conduction defect after transcatheter aortic valve implantation on left ventricular function. JACC Cardiovasc Interv. 2012;5:1257-63.
6. Kodali SK, Williams MR, Smith CR, Svensson LG, Webb JG, Makkar RR, Fontana GP, Dewey TM, Thourani VH, Pichard AD, Fischbein M, Szeto WY, Lim S, Greason KL, Teirstein PS, Malaisrie SC, Douglas PS, Hahn RT, Whisenant B, Zajarias A, Wang D, Akin JJ, Anderson WN, Leon MB; PARTNER Trial Investigators. Two-year outcomes after transcatheter or surgical aortic-valve replacement. N Engl J Med. 2012;366:1686-95.
7. Vasques F, Messori A, Lucenteforte E, Biancari F. Immediate and late outcome of patients aged 80 years and older undergoing isolated aortic valve replacement: a systematic review and meta-analysis of 48 studies. Am Heart J. 2012;163:477-85.
8. Kempfert J, Rastan AJ, Mohr FW, Walther T. A new self-expanding transcatheter aortic valve for transapical implantation-first in man implantation of the JenaValveTM. Eur J Cardiothorac Surg. 2011;40:761-3.
9. Kempfert JR, Rastan AJ, Beyersdorf F, Schönburg M, Schuler G, Sorg S, Mohr FW, Walther T. Trans-apical aortic valve implantation using a new self-expandable bioprosthesis: initial outcomes. Eur J Cardiothorac Surg. 2011;40:1112-7.